Literature DB >> 21744231

The growth hormone receptor polymorphism in patients with acromegaly: relationship to BMI and glucose metabolism.

Sebahat Turgut1, Fulya Akın, Ceylan Ayada, Senay Topsakal, Emrah Yerlikaya, Günfer Turgut.   

Abstract

The aim of this study was to investigate association between the frequencies of Growth Hormone receptor (d3GHR) gene polymorphisms and some clinical parameters of acromegalic patients. Total of 35 acromegalic patients were enrolled to study. The d3GHR polymorphism was identified by using polymerase chain reaction from peripheral blood samples. The levels of systolic and diastolic blood pressure, BMI, fasting plasma glucose (FPG), Fasting insulin, HOMA-IR, IGF-I, GH, IGFBP3, triglyceride, HDL and LDL cholesterol concentrations were evaluated. The frequencies of d3GHR genotypes were found as follows; 5 (14.3%) subjects had d3/d3, 11 (31.4%) had d3/fl and 19 (54.3%) had fl/fl in patients. The prevalence of the d3 and fl alleles was 30 and 70%, respectively. Systolic blood pressure, fasting insulin and HOMA-IR was found significantly increased in homozygote d3GHR genotype group compared to d3/fl subjects (P < 0.05). In addition, BMI was observed significantly different among three genotypes (P = 0.007) and in the subjects with d3/d3 genotype, BMI was found significantly higher than d3/fl and fl/fl genotypes groups. As well as, no significant difference was found between the d3 and fl alleles group in terms of the clinical parameters except for BMI (P = 0.002). It can be said that the d3GHR gene polymorphism may affect BMI, systolic blood pressure and insulin regulation. At the same time we can say homozygote d3GHR genotype and d3 allele carriers may have more risk than other genotypes for high BMI.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21744231     DOI: 10.1007/s11102-011-0329-9

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  28 in total

Review 1.  Effects of growth hormone on fluid homeostasis. Clinical and experimental aspects.

Authors:  Jens Møller
Journal:  Growth Horm IGF Res       Date:  2003 Apr-Jun       Impact factor: 2.372

2.  Growth hormone (GH) pharmacogenetics: influence of GH receptor exon 3 retention or deletion on first-year growth response and final height in patients with severe GH deficiency.

Authors:  Alexander A L Jorge; Frederico G Marchisotti; Luciana R Montenegro; Luciani R Carvalho; Berenice B Mendonca; Ivo J P Arnhold
Journal:  J Clin Endocrinol Metab       Date:  2005-11-15       Impact factor: 5.958

3.  The d3-growth hormone (GH) receptor polymorphism is associated with increased responsiveness to GH in Turner syndrome and short small-for-gestational-age children.

Authors:  G Binder; F Baur; R Schweizer; M B Ranke
Journal:  J Clin Endocrinol Metab       Date:  2005-11-15       Impact factor: 5.958

4.  d3-Growth hormone receptor polymorphism in acromegaly: effects on metabolic phenotype.

Authors:  Laura Montefusco; Marcello Filopanti; Cristina L Ronchi; Luca Olgiati; Carmen La-Porta; Marco Losa; Paolo Epaminonda; Francesca Coletti; Paolo Beck-Peccoz; Anna Spada; Andrea G Lania; Maura Arosio
Journal:  Clin Endocrinol (Oxf)       Date:  2010-05       Impact factor: 3.478

Review 5.  Current concepts in the biochemical assessment of the patient with acromegaly.

Authors:  Pamela U Freda
Journal:  Growth Horm IGF Res       Date:  2003-08       Impact factor: 2.372

6.  Common exon 3 polymorphism of the GH receptor (GHR) gene and effect of GH therapy on growth in Korean children with idiopathic short stature (ISS).

Authors:  Jung Min Ko; Jung Young Park; Han-Wook Yoo
Journal:  Clin Endocrinol (Oxf)       Date:  2009-01       Impact factor: 3.478

7.  Clinical and biochemical impact of the d3 growth hormone receptor genotype in acromegaly.

Authors:  Moisés Mercado; Baldomero González; Carolina Sandoval; Yoshua Esquenazi; Fernando Mier; Guadalupe Vargas; Ana Laura Espinosa de los Monteros; Ernesto Sosa
Journal:  J Clin Endocrinol Metab       Date:  2008-07-08       Impact factor: 5.958

8.  D3 GH receptor polymorphism is not associated with IGF1 levels in untreated acromegaly.

Authors:  Peter Kamenicky; Christine Dos Santos; Consuelo Espinosa; Sylvie Salenave; Françoise Galland; Yves Le Bouc; Patrick Maison; Pierre Bougnères; Philippe Chanson
Journal:  Eur J Endocrinol       Date:  2009-05-13       Impact factor: 6.664

9.  Genetic association study of growth hormone receptor and idiopathic scoliosis.

Authors:  Xu S Qiu; Nelson L S Tang; Hiu-Yan Yeung; Yong Qiu; Jack C Y Cheng
Journal:  Clin Orthop Relat Res       Date:  2007-09       Impact factor: 4.176

10.  The common exon 3 polymorphism of the growth hormone receptor gene and the effect of growth hormone therapy on growth in Korean patients with Turner syndrome.

Authors:  Jung Min Ko; Jae-Min Kim; Chong-Kun Cheon; Duk-Hee Kim; Dae-Yeol Lee; Woo Yeong Cheong; Eun Young Kim; Mi Jung Park; Han-Wook Yoo
Journal:  Clin Endocrinol (Oxf)       Date:  2009-08-04       Impact factor: 3.478

View more
  11 in total

1.  Exon 3-deleted growth hormone receptor isoform is not related to worse bone mineral density or microarchitecture or to increased fracture risk in acromegaly.

Authors:  J Pontes; M Madeira; C H A Lima; L L Ogino; F de Paula Paranhos Neto; L M C de Mendonça; M L F Farias; L Kasuki; M R Gadelha
Journal:  J Endocrinol Invest       Date:  2019-08-07       Impact factor: 4.256

2.  Influence of growth hormone receptor (GHR) exon 3 and -202A/C IGFBP-3 genetic polymorphisms on clinical and biochemical features and therapeutic outcome of patients with acromegaly.

Authors:  Raquel S Jallad; Ericka B Trarbach; Felipe H Duarte; Alexander A L Jorge; Marcello D Bronstein
Journal:  Pituitary       Date:  2015-10       Impact factor: 4.107

3.  HOMA-IR in acromegaly: a systematic review and meta-analysis.

Authors:  Betina Biagetti; Anna Aulinas; Anna Casteras; Santiago Pérez-Hoyos; Rafael Simó
Journal:  Pituitary       Date:  2020-10-21       Impact factor: 4.107

4.  Growth hormone receptor exon 3 isoforms may have no importance in the clinical setting of multiethnic Brazilian acromegaly patients.

Authors:  Evelyn de Oliveira Machado; Carlos Henrique Azeredo Lima; Liana Lumi Ogino; Leandro Kasuki; Mônica R Gadelha
Journal:  Pituitary       Date:  2016-08       Impact factor: 4.107

5.  The clinical and cardiometabolic effects of d3-growth hormone receptor polymorphism in acromegaly.

Authors:  Nese Cinar; Selcuk Dagdelen; Hikmet Yorgun; Ugur Canpolat; Giray Kabakçı; Tomris Erbas
Journal:  Pituitary       Date:  2015-02       Impact factor: 4.107

6.  Association between the Growth Hormone Receptor Exon 3 Polymorphism and Metabolic Factors in Korean Patients with Acromegaly.

Authors:  Hye Yoon Park; In Ryang Hwang; Jung Bum Seo; Su Won Kim; Hyun Ae Seo; In Kyu Lee; Jung Guk Kim
Journal:  Endocrinol Metab (Seoul)       Date:  2015-01-05

7.  Association between FTO gene polymorphisms and HDL cholesterol concentration may cause higher risk of cardiovascular disease in patients with acromegaly.

Authors:  Aleksandra Franczak; Katarzyna Kolačkov; Aleksandra Jawiarczyk-Przybyłowska; Marek Bolanowski
Journal:  Pituitary       Date:  2018-02       Impact factor: 4.107

Review 8.  Predictors of Quality of Life in Acromegaly: No Consensus on Biochemical Parameters.

Authors:  Victor J Geraedts; Cornelie D Andela; Günter K Stalla; Alberto M Pereira; Wouter R van Furth; Caroline Sievers; Nienke R Biermasz
Journal:  Front Endocrinol (Lausanne)       Date:  2017-03-03       Impact factor: 5.555

9.  Exon 3-deleted and full-length growth hormone receptor polymorphism frequencies in an Iranian population.

Authors:  A A Palizban; M Radmansorry; M Bozorgzad
Journal:  Res Pharm Sci       Date:  2014 Nov-Dec

10.  Frequency of the exon 3-deleted/full-length growth hormone receptor polymorphism in Saudi Arabian population.

Authors:  Yahia A Kaabi
Journal:  Saudi Med J       Date:  2017-11       Impact factor: 1.484

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.